73 reports of this reaction
1.5% of all AMPICILLIN SODIUM AND SULBACTAM SODIUM reports
#11 most reported adverse reaction
ANAEMIA is the #11 most commonly reported adverse reaction for AMPICILLIN SODIUM AND SULBACTAM SODIUM, manufactured by Roerig. There are 73 FDA adverse event reports linking AMPICILLIN SODIUM AND SULBACTAM SODIUM to ANAEMIA. This represents approximately 1.5% of all 4,969 adverse event reports for this drug.
Patients taking AMPICILLIN SODIUM AND SULBACTAM SODIUM who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for AMPICILLIN SODIUM AND SULBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for AMPICILLIN SODIUM AND SULBACTAM SODIUM:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 73 FDA reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 1.5% of all adverse event reports for AMPICILLIN SODIUM AND SULBACTAM SODIUM, making it a notable side effect.
If you experience anaemia while taking AMPICILLIN SODIUM AND SULBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.